EHRA-PATHS: Clinical and Health Economic Evaluation of New Care Pathways

Sponsor
University Medical Center Groningen (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05773768
Collaborator
(none)
1,300
2
16

Study Details

Study Description

Brief Summary

In elderly atrial fibrillation (AF) patients, AF is usually a manifestation of risk factors and comorbidities not only limited to cardiovascular diseases. Especially in elderly often more than two comorbidities are present. The presence of comorbidities also affects outcomes in AF patients. Current healthcare systems are single-disease focused, which increases the risk of underdiagnosing, replicating diagnostic tests and adverse drug-drug interactions, placing a high burden on healthcare costs. Healthcare systems and hospitals are in need of new care pathways to address the complexity of multimorbid AF patients and to reduce costs. The EHRA-PATHS consortium set out to address this need for change in management for multimorbid, elderly AF patients in Europe through the development of new care pathways. The aim of this study is to evaluate the current management of risk factors and comorbidities, and subsequently implement the newly developed care pathways and evaluate if these pathways lead to better management of risk factors and comorbidities in multimorbid, elderly AF patients, compared to current standard care.

Condition or Disease Intervention/Treatment Phase
  • Device: EHRA-PATHS software tool
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1300 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
EHRA-PATHS: Addressing Multimorbidity in Elderly Atrial Fibrillation Patients Through Interdisciplinary, Patient-centred Systematic Care Pathways - Clinical and Health Economic Evaluation of New Care Pathways
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Jan 1, 2025
Anticipated Study Completion Date :
Jan 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: New care program

The health care provider will use the EHRA-PATHS' newly developed care pathways to assess whether there is an indication for presence of risk factors and comorbidities. If this is the case, the care pathways will show possible next steps for confirming the presence of these risk factors and comorbidities. If confirmed, treatment according to the current guidelines should be initiated. Since this leads to an individualized management plan, procedures can differ between patients and will also depend on local processes.

Device: EHRA-PATHS software tool
Newly developed care pathways integrated into a care-management software tool

No Intervention: Routine clinical care

The health care provider follows current clinical practice with regards to history taking, physical examination etc.

Outcome Measures

Primary Outcome Measures

  1. Identification and management of risk factors and comorbidities [6 months]

    The number of risk factors and comorbidities that are identified and for which treatment is initiated during base mapping and at the end of the randomized controlled trial.

Secondary Outcome Measures

  1. AF symptom burden [6 months]

    Measured with the Atrial Fibrillation Severity Scale (AFSS) questionnaire

  2. Quality of life (QoL) [6 months]

    Measured with the EuroQol five-dimensional five-level (EQ-5D-5L) questionnaire

  3. Referrals to other disciplines [6 months]

    The referrals to other disciplines will consist of the number of referrals and the percentage of patients referred.

  4. Patient and health care provider satisfaction [6 months]

    Measured with a patient and health care provider (HCP) satisfaction questionnaire

  5. Healthcare resource use/costs [6 months]

    Measured with the iMedical Consumption Questionnaire (iMCQ)

  6. HRQoL/utility [6 months]

    Measured with the EQ-5D-5L questionnaire (iMCQ)

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Newly diagnosed atrial fibrillation (paroxysmal, persistent or permanent)

  • ≥65 years of age

  • Willing and able to participate and to attend the scheduled follow-up visits.

Exclusion Criteria:
  • Atrial fibrillation episode was due to a trigger (i.e. postoperative, infection, hyperthyroidism etc.)

  • Life expectancy of less than 1 year

  • Participation in another clinical study (registry studies not included)

  • Severe cognitive impairment / dementia (defined based on MMSE and CDR scoring systems)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University Medical Center Groningen

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Medical Center Groningen
ClinicalTrials.gov Identifier:
NCT05773768
Other Study ID Numbers:
  • EHRA-PATHS
First Posted:
Mar 17, 2023
Last Update Posted:
Mar 17, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 17, 2023